Literature DB >> 22791128

Quantitative profiling of CpG island methylation in human stool for colorectal cancer detection.

Giles O Elliott1, Ian T Johnson, Jane Scarll, Jack Dainty, Elizabeth A Williams, D Garg, Amanda Coupe, David M Bradburn, John C Mathers, Nigel J Belshaw.   

Abstract

PURPOSE: The aims of this study were to investigate the use of quantitative CGI methylation data from stool DNA to classify colon cancer patients and to relate stool CGI methylation levels to those found in corresponding tissue samples.
METHODS: We applied a quantitative methylation-specific PCR assay to determine CGI methylation levels of six genes, previously shown to be aberrantly methylated during colorectal carcinogenesis. Assays were performed on DNA from biopsies of "normal" mucosa and stool samples from 57 patients classified as disease-free, adenoma, or cancer by endoscopy, and in tumour tissue from cancer patients. Additionally, CGI methylation was analysed in stool DNA from an asymptomatic population of individuals covering a broad age range (mean = 47 ± 24 years)
RESULTS: CGI methylation levels in stool DNA were significantly higher than in DNA from macroscopically normal mucosa, and a significant correlation between stool and mucosa was observed for ESR1 only. Multivariate statistical analyses using the methylation levels of each CGI in stool DNA as a continuous variable revealed a highly significant (p = 0.003) classification of cancer vs. non-cancer (adenoma + disease-free) patients (sensitivity = 65 %, specificity = 81 %).
CONCLUSION: CGI methylation profiling of stool DNA successfully identified patients with cancer despite the methylation status of CGIs in stool DNA not generally reflecting those in DNA from the colonic mucosa.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22791128     DOI: 10.1007/s00384-012-1532-5

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  52 in total

1.  Methylation changes in faecal DNA: a marker for colorectal cancer screening?

Authors:  Hannes M Müller; Michael Oberwalder; Heidi Fiegl; Maria Morandell; Georg Goebel; Matthias Zitt; Markus Mühlthaler; Dietmar Ofner; Raimund Margreiter; Martin Widschwendter
Journal:  Lancet       Date:  2004-04-17       Impact factor: 79.321

2.  Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population.

Authors:  Thomas F Imperiale; David F Ransohoff; Steven H Itzkowitz; Barry A Turnbull; Michael E Ross
Journal:  N Engl J Med       Date:  2004-12-23       Impact factor: 91.245

3.  Accelerated age-related CpG island methylation in ulcerative colitis.

Authors:  J P Issa; N Ahuja; M Toyota; M P Bronner; T A Brentnall
Journal:  Cancer Res       Date:  2001-05-01       Impact factor: 12.701

4.  Detection of APC mutations in fecal DNA from patients with colorectal tumors.

Authors:  Giovanni Traverso; Anthony Shuber; Bernard Levin; Constance Johnson; Louise Olsson; David J Schoetz; Stanley R Hamilton; Kevin Boynton; Kenneth W Kinzler; Bert Vogelstein
Journal:  N Engl J Med       Date:  2002-01-31       Impact factor: 91.245

5.  Detection of hypermethylated DNA or cyclooxygenase-2 messenger RNA in fecal samples of patients with colorectal cancer or polyps.

Authors:  Wai K Leung; Ka-Fai To; Ellen P S Man; Michael W Y Chan; Aric J Hui; Simon S M Ng; James Y W Lau; Joseph J Y Sung
Journal:  Am J Gastroenterol       Date:  2007-03-22       Impact factor: 10.864

Review 6.  Cell exfoliation in the human colon: myth, reality and implications for colorectal cancer screening.

Authors:  Alexandre Loktionov
Journal:  Int J Cancer       Date:  2007-06-01       Impact factor: 7.396

7.  Aging and DNA methylation in colorectal mucosa and cancer.

Authors:  N Ahuja; Q Li; A L Mohan; S B Baylin; J P Issa
Journal:  Cancer Res       Date:  1998-12-01       Impact factor: 12.701

8.  GATA4 and GATA5 are potential tumor suppressors and biomarkers in colorectal cancer.

Authors:  Debby M E I Hellebrekers; Marjolein H F M Lentjes; Sandra M van den Bosch; Veerle Melotte; Kim A D Wouters; Kathleen L J Daenen; Kim M Smits; Yoshimitsu Akiyama; Yasuhito Yuasa; Silvia Sanduleanu; Carolina A J Khalid-de Bakker; Daisy Jonkers; Matty P Weijenberg; Joost Louwagie; Wim van Criekinge; Beatriz Carvalho; Gerrit A Meijer; Stephen B Baylin; James G Herman; Adriaan P de Bruïne; Manon van Engeland
Journal:  Clin Cancer Res       Date:  2009-06-09       Impact factor: 12.531

9.  Hypermethylation of SFRP2 as a potential marker for stool-based detection of colorectal cancer and precancerous lesions.

Authors:  Zhaohui Huang; Lihua Li; Jinfu Wang
Journal:  Dig Dis Sci       Date:  2007-04-05       Impact factor: 3.199

10.  A CpG island hypermethylation profile of primary colorectal carcinomas and colon cancer cell lines.

Authors:  Guro E Lind; Lin Thorstensen; Tone Løvig; Gunn I Meling; Richard Hamelin; Torleiv O Rognum; Manel Esteller; Ragnhild A Lothe
Journal:  Mol Cancer       Date:  2004-10-11       Impact factor: 27.401

View more
  4 in total

Review 1.  Advances in epigenetic biomarker research in colorectal cancer.

Authors:  Xi Wang; Ye-Ye Kuang; Xiao-Tong Hu
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

Review 2.  DNA Methylation as a Noninvasive Epigenetic Biomarker for the Detection of Cancer.

Authors:  Catherine Leygo; Marissa Williams; Hong Chuan Jin; Michael W Y Chan; Wai Kit Chu; Michael Grusch; Yuen Yee Cheng
Journal:  Dis Markers       Date:  2017-09-05       Impact factor: 3.434

Review 3.  Epigenetics Analysis and Integrated Analysis of Multiomics Data, Including Epigenetic Data, Using Artificial Intelligence in the Era of Precision Medicine.

Authors:  Ryuji Hamamoto; Masaaki Komatsu; Ken Takasawa; Ken Asada; Syuzo Kaneko
Journal:  Biomolecules       Date:  2019-12-30

4.  Potential of DNA methylation in rectal cancer as diagnostic and prognostic biomarkers.

Authors:  Ruth Exner; Walter Pulverer; Martina Diem; Lisa Spaller; Laura Woltering; Martin Schreiber; Brigitte Wolf; Markus Sonntagbauer; Fabian Schröder; Judith Stift; Fritz Wrba; Michael Bergmann; Andreas Weinhäusel; Gerda Egger
Journal:  Br J Cancer       Date:  2015-09-03       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.